Azacitidine (5-Azacytidine)

For research use only.

Catalog No.S1782 Synonyms: 5-AzaC,Ladakamycin

23 publications

Azacitidine (5-Azacytidine) Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Azacitidine (5-Azacytidine) has been cited by 23 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH4UnUxNjFvNUCg{txO M4\jSFEzNTd{IHi= NYXtO2ptcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mm[2NlYyOzN{NE[=
Jurkat  M2XBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\6cVAvOS13MDFOwG0> MnrzNVIuPzJiaB?= NFns[mRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NFO1fGEzPjF|M{K0Oi=>
CA46 NUeyPVh3TnWwY4Tpc44hSXO|YYm= M4XROlIxyqEEtV2= MoLMOFghcA>? NEjrfmtqdmO{ZXHz[ZPDqFCWUFyxxsBuWk6DIHX4dJJme3Orb36= MVmyOlE{OzJ2Nh?=
Raji  MWHGeY5kfGmxbjDBd5NigQ>? M{LjdVE2yqEEtV2= MkXPOFghcA>? NWjCVphucW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u NV7jN4V{OjZzM{OyOFY>
Jurkat  NU\KZXBWTnWwY4Tpc44hSXO|YYm= NGji[2I{NjYEoNM1US=> MljIOFghcA>? NX\ZeXNpcW6lcnXhd4V{yqCSVGDMNeKhdVKQQTDlfJBz\XO|aX;u NG\HU|YzPjF|M{K0Oi=>
MDA-MB-231 MnXLSpVv[3Srb36gRZN{[Xl? M1XtdFEwOi53L{Wg{txO M2XYelQ5KGh? MXXk[YNz\WG|ZYOgeIhmKFCWUF6xNkBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kA2yqEQvF2gOFjDqGh? NYLZZngyOjV6MUeyNlk>
MDA-MB-231 MV\GeY5kfGmxbjDBd5NigQ>? NHHYXYUyNzJwNT:1JO69VQ>? MlqxOFghcA>? M3\pcYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFWtZ4FlcGW{aX6gcXJPSSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOi53wrFOwG1nd3JiNElCpIg> MUOyOVgyPzJ{OR?=
MDA-MB-231 M1fC[GZ2dmO2aX;uJGF{e2G7 NHrK[FMyNzJwNT:1JO69VQ>? NWjWS5BpOjRxNEigbC=> M4HZUYlv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=> MUOyOVgyPzJ{OR?=
MCF-7 M3nhcWZ2dmO2aX;uJGF{e2G7 NU\weFE1OS9{LkWvOUDPxE1? MX2yOE81QCCq M4jCPIlv[3KnYYPld{BRSVKSIHPs[YF3[WenwrC= NUXEOXF5OjV6MUeyNlk>
MDA-MB-231  M2rJW2Z2dmO2aX;uJGF{e2G7 Mn;MNU8zNjVxNTFOwG0> M1P5T|I1NzR6IHi= MUPpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gcYlTVkFvMUK0JIF1KHSqZTDjc45k\XKwdILheIlwdiCxZjC1JO69VQ>? MlvaNlU5OTd{Mkm=
A498 NHjJPJJHfW6ldHnvckBCe3OjeR?= M1jvdlExKML3TR?= NFXxPJE4OiCq NGHod5dqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NGnZPWQzPTV4OUC4Oi=>
CaKI-2 NH24VJBHfW6ldHnvckBCe3OjeR?= MY[xNEDDvU1? M1L2SVczKGh? NIjzTWtqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NH\WdlEzPTV4OUC4Oi=>
Ketr-3 MWLGeY5kfGmxbjDBd5NigQ>? MYOxNEDDvU1? MUi3NkBp MmHNbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u NGDVUGozPTV4OUC4Oi=>
A253 NG\udY1HfW6ldHnvckBCe3OjeR?= NUfZZVEzOTBiwsXN NYHS[IJqOC12IHS= MWXpcoNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBt\X[nbDDv[kB1cGViTUPSxsBi\nSncjCyOEBp MUWyOVQ5PTV|Nh?=
A253 MnOzSpVv[3Srb36gRZN{[Xl? MnfLNVAhyrWP NFvzdpY4OiCq MV3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{ MlrVNlU1QDV3M{[=
A253 NG[3em5HfW6ldHnvckBCe3OjeR?= M4fETVExKML3TR?= M3fodFAuPCCm M2P5c5Jm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=> NV3xTGlHOjV2OEW1N|Y>
PC3 NYjmTXFtTnWwY4Tpc44hSXO|YYm= NHSxeYQxNjJizszNxsA> MVu0JIQ> Mkj3bY5kemWjc3XzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiSVfGRnA4NCCVRmLQNUBidmRiU1zDOmEyPSClb33ibY5m\CC5aYToJGdUUzF{Nh?= MlLQNlU1Pzd|NEC=
MCF7 NULGcHM1TnWwY4Tpc44hSXO|YYm= Mn;NNE4{KM7:TdMg M4O1eFQh\A>? NIi4coVqdmO{ZXHz[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDJS2ZDWDduIGPGVnAyKGGwZDDTUGM3STF3IHPvcYJqdmWmIIfpeIghT1ONMUK2 NYfGdZdFOjV2N{ezOFA>
PC3 NETnVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWNE4zKM7:TdMg MXW0JIQ> MnrM[IVkemWjc3XzJJRp\SClZXzsJIdzd3e2aDD0c{AzOC5|JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> NE[1c3UzPTR5N{O0NC=>
MCF7 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrtdJkxNjNizszNxsA> Mn3SOEBl NH3lOnVl\WO{ZXHz[ZMhfGinIHPlcIwh\3Kxd4ToJFI1NjhnIHPvcYJqdmWmIIfpeIghT1ONMUK2 M3fiZVI2PDd5M{Sw
BGC-823 MnfaSpVv[3Srb36gRZN{[Xl? MXG1xsDPxE1? NXzu[WVYPzJiaB?= Mo\6[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> MXqyOVQ4PTd|Mx?=
MKN28 MUjGeY5kfGmxbjDBd5NigQ>? M4P5dFXDqM7:TR?= NIHQfWE4OiCq NFfnblJl\WO{ZXHz[ZMhfGinIGDSUE0{KHC{b4TlbY4hdGW4ZXygd4lodmmoY3HueIx6 M2H0VFI2PDd3N{Oz
SGC-7901 NYP4OINLTnWwY4Tpc44hSXO|YYm= NXzBS|E5PcLizszN M3K1WFczKGh? MVrk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 M1PkT|I2PDd3N{Oz
MKN45 MnHTSpVv[3Srb36gRZN{[Xl? M4DGflXDqM7:TR?= M2G2NVczKGh? NX\3[ZJq\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? M{W5XFI2PDd3N{Oz
BGC-823 NGrifnRHfW6ldHnvckBCe3OjeR?= MWW1xsDPxE1? MYm3NkBp NUjrNpQ5\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> M{f3PFI2PDd3N{Oz
MKN28 Mnz2SpVv[3Srb36gRZN{[Xl? NVLC[GpTPcLizszN MkKzO|IhcA>? NV\KWFJr\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> M4XJcVI2PDd3N{Oz
SGC-7901 Mn3JSpVv[3Srb36gRZN{[Xl? MUG1xsDPxE1? M2rrTlczKGh? NWTaZ4hl\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> MV2yOVQ4PTd|Mx?=
MKN45 NFj2dGFHfW6ldHnvckBCe3OjeR?= M4jTdlXDqM7:TR?= MmGyO|IhcA>? MY\k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M1LtVlI2PDd3N{Oz
HREC NELWPFBHfW6ldHnvckBCe3OjeR?= M4jjW|UwOTEEoN88US=> NEm2d3I1QCCq Mke0bY5lfWOnczDQSWRHKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnzwNlU{PTJ5NEe=
HRPE M2X6VWZ2dmO2aX;uJGF{e2G7 MV61M|ExyqEQvF2= M2rXNFQ5KGh? NXv5PXRPcW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4DMdVI2OzV{N{S3
HREC NHLC[IpHfW6ldHnvckBCe3OjeR?= MV61M|ExyqEQvF2= NVfLOoJoPDhiaB?= NVzIb2p4\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWNCVS1zIDjuc5QheHKxdHXpckBt\X[nbDDpckBJWlCHIHPlcIx{MSxiSVytNe6zKGSxc3Wt[IVx\W6mZX70cJk> MnH6NlU{PTJ5NEe=
HRPE M{O2RWZ2dmO2aX;uJGF{e2G7 MYC1M|ExyqEQvF2= MWO0PEBp M1;MSYRwf25vcnXneYxifGW|IH;mJHZGT0ZuIFnMMVHPuixiYX7kJG1OWDJiZH;z[U1l\XCnbnTlcpRtgQ>? NFTybIozPTN3Mke0Oy=>
MSCs MWTGeY5kfGmxbjDBd5NigQ>? NIC5NHoyOCEQvF2= MX:yOEBp M1m1U5Bzd22xdHXzJJRp\SClb33tbZRu\W62IH;mJG1US3NidH:gcZlw[2G{ZHnhcEBlcW[oZYLlcpRq[XSrb36= NXP3eWw{OjV|NUGzPVU>
HL-60 M4\LTmZ2dmO2aX;uJGF{e2G7 NHHCWlA2KM7:TR?= NXnRfFlCPzJiaB?= MoXYSG1UVw>? MWjzbYdvcW[rY3HueIx6KHWycnXneYxifGW|IGrOSlM5OiCneIDy[ZN{cW:w NUPNdY5kOjV|MUmwOFk>
MV4-11 MVXGeY5kfGmxbjDBd5NigQ>? NFnmfGQ2KM7:TR?= NE\LboM4OiCq Mlf2SG1UVw>? M3G5ZZNq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36= MWmyOVMyQTB2OR?=
A2780 Mme3SpVv[3Srb36gRZN{[Xl? MWq1JOK2VcLi MnfsO{Bl MYLpcoNz\WG|ZYOgSG5CKG2ndHj5cIF1cW:wIHzleoVt M4XsS|I2Ojl7Nkm0
CP70 M3L3eWZ2dmO2aX;uJGF{e2G7 NIP0ZYM2KML3TdMg M1;VfVch\A>? MmDvbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>? MVqyOVI6QTZ7NB?=
A2780 NVv6OZdUTnWwY4Tpc44hSXO|YYm= M1LHTFUhyrWPwrC= NGq2XXo4KGR? MXX3[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? NWPi[Wh7OjV{OUm2PVQ>
CP70 NXX5c5VQTnWwY4Tpc44hSXO|YYm= M1WxSFUhyrWPwrC= NVy3cZRkPyCm MVT3[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? MnHqNlUzQTl4OUS=
OCM3 NHjS[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjRdosxNjVxMT:yJO69VQ>? MVS3JIQ> MXzEUXNQ NXr1b3hpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHPne3AzPTF2Nkm4NS=>
92.1 M2LCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrjcpZ[OC53L{GvNkDPxE1? MV63JIQ> MoT0SG1UVw>? NWLsRYw3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NFnZeIQzPTF2Nkm4NS=>
OCM1 NEHoV5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;ONE42NzFxMjFOwG0> M4TGelch\A>? M3nyNmROW09? M1fm[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MWqyOVE1Pjl6MR?=
OMM1 NF\rU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjnWGoxNjVxMT:yJO69VQ>? MnW2O{Bl MmTFSG1UVw>? MnXUbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MV:yOVE1Pjl6MR?=
Mel 285 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmwMlUwOS9{IN88US=> MnjaO{Bl MUjEUXNQ M1;HXolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkTCNlUyPDZ7OEG=
Mel 290 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHtSYQxNjVxMT:yJO69VQ>? M3XIdVch\A>? M4m2RWROW09? NIL4PJpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NW[1UI4{OjVzNE[5PFE>
OCM3 NIW3U5RHfW6ldHnvckBCe3OjeR?= NGnIU5gxNjVxMTFOwG0> NH7hR2U1QCCq MoTlSG1UVw>? M13aTIRm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? MXKyOVE1Pjl6MR?=
92.1 MV7GeY5kfGmxbjDBd5NigQ>? MU[wMlUwOSEQvF2= MnXLOFghcA>? M3nGWWROW09? NXzhVmpZ\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= NH;LemIzPTF2Nkm4NS=>
OCM1 M3K3[mZ2dmO2aX;uJGF{e2G7 MlTNNE42NzFizszN NEnvPHA1QCCq MljPSG1UVw>? Ml7P[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? Mm\RNlUyPDZ7OEG=
OMM1 NHq1c2pHfW6ldHnvckBCe3OjeR?= MlHWNE42NzFizszN MYG0PEBp M1;XPGROW09? NW\IWGVs\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= NELTO2IzPTF2Nkm4NS=>
Mel 285 MluxSpVv[3Srb36gRZN{[Xl? NEnJXWkxNjVxMTFOwG0> NX3NeYt[PDhiaB?= M3jmNGROW09? MVnk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 M2ezbFI2OTR4OUix
Mel 290 MU\GeY5kfGmxbjDBd5NigQ>? NG\4eZMxNjVxMTFOwG0> M4\0TFQ5KGh? MXTEUXNQ M3K0Z4Rm[3KnYYPld{BkdG:wb3flcolkcXS7IHTvd4Uu\GWyZX7k[Y51dHl? M4DhZ|I2OTR4OUix
OCM3 MVXGeY5kfGmxbjDBd5NigQ>? Mny2NE42NzFizszN M2HIVVQ5KGh? MWTEUXNQ MXXk[YNz\WG|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg NWfKOVY6OjVzNE[5PFE>
Mel 290 MnHaSpVv[3Srb36gRZN{[Xl? NHLPXpcxNjVxMTFOwG0> MUG0PEBp MkSzSG1UVw>? NUm4VIFs\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? M1\CUVI2OTR4OUix
OMM1 M4P3UWZ2dmO2aX;uJGF{e2G7 MV6wMlUwOSEQvF2= NFy0Uow1QCCq NGXLW4JFVVOR NGLUbmZl\WO{ZXHz[ZMhcW64YYPpc44h\G:|ZTDk[ZBmdmSnboTsfeKh NXrKbox2OjVzNE[5PFE>
OCM1 M2CyTmNmdGxiVnnhZoltcXS7IFHzd4F6 MVOwMlUwOSEQvF2= NFHUTVE2KGR? NG\WOpRFVVOR MWXk[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= Mo\xNlUyPDZ7OEG=
92.1 MkjpR4VtdCCYaXHibYxqfHliQYPzZZk> MUSwMlUwOSEQvF2= NWT6WXpnPSCm M3vGPWROW09? M2LXb4Rm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u M2rSTlI2OTR4OUix
OCM1 M3rGWmZ2dmO2aX;uJGF{e2G7 M{O0bVAvPS9zIN88US=> NV;YfIV1PDhiaB?= NGnndVZFVVOR NFfJSVFk[XW|ZYOg[4xw[mGuIFTORUBpgXCxbXX0bJlt[XSrb36gZZQhVC1zIILldIVifCCub3Pp NWX0emZ7OjVzNE[5PFE>
OCM3 MorISpVv[3Srb36gRZN{[Xl? NHL0ZWcxNjVxMTFOwG0> MkfHOFghcA>? M2TabWROW09? MoXoZ4F2e2W|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?= NYLjNotUOjVzNE[5PFE>
92.1 MUPGeY5kfGmxbjDBd5NigQ>? M2DPSVAvPS9zIN88US=> M2jVTVQ5KGh? Mli0SG1UVw>? M13SRYNifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= NYfUT2REOjVzNE[5PFE>
IMR32 NG\h[IdHfW6ldHnvckBCe3OjeR?= Ml;KN{DPxE1? M1\kWFczKGh? MmjlSG1UVw>? MnzjbY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 NX3FfFg6OjVzMES4OVA>
IMR5-75 M2HidWZ2dmO2aX;uJGF{e2G7 M2HOZVMh|ryP NVjsWVhtPzJiaB?= NYfoSFl5TE2VTx?= Mmi3bY5lfWOnc9MgdFE6NUmQS{TkxsBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 NFG0eYMzPTFyNEi1NC=>
Be(2)-C MYDGeY5kfGmxbjDBd5NigQ>? MnzwN{DPxE1? M4\ZeVczKGh? NWDpU|RRTE2VTx?= M4TvOolv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> MWOyOVExPDh3MB?=
Bxpc-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr2eVY2NzFyIN88US=> NYLEfo0zOjRxNEivO|IhcA>? Mor2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK| MoH6NlUxPjF5M{G=
Bxpc-3 NUnLeXZVSXCxcITvd4l{KEG|c3H5 NV3pdpp7PS9zMDFOwG0> NHXLbXQzPC92OD:3NkBp NHPMd3ZqdmS3Y3XzJIFxd3C2b4Ppd{BqdiC2aX3lMUBidmRiY3;uZ4VzdnS{YYTpc44hdWGwbnXydy=> M4XIeFI2ODZzN{Ox
Bxpc-3 M17oSGZ2dmO2aX;uJGF{e2G7 NYfLdG9pPS9zMDFOwG0> M131UFI1NzR6L{eyJIg> NXnHT4dt\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo M2PKSlI2ODZzN{Ox
Bxpc-3 MVPGeY5kfGmxbjDBd5NigQ>? NVPzcJJPPS9zMDFOwG0> M4LjRVI1NzR6L{eyJIg> M3T6NYRm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2= M4HUfVI2ODZzN{Ox
Bxpc-3 MXfGeY5kfGmxbjDBd5NigQ>? M3ro[|UwOTBizszN M4L0clI1NzR6L{eyJIg> MoK1[I94di2{ZXf1cIF1\VNiYz3tfYMhdVKQQTDlfJBz\XO|aX;uJIlvKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYLz Ml\UNlUxPjF5M{G=
HL-60 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfVNU4xKM7:TR?= M1r2ZlQ5KGh? MlTGd4lodmmoaXPhcpRtgSCrbnjpZol1eyCKTD22NEBk\WyuIHfyc5d1cMLi NGHNUHMzPTB3MUGxPS=>
HL-60 M1XWR2Z2dmO2aX;uJGF{e2G7 MonxNU4xKM7:TR?= NEDmOoY1QCCq MmrMbY5kemWjc3XzJJAzOVeDRkGvR2lROcLiYX7kJINie3Cjc3WtN{BmgHC{ZYPzbY9vyqB? M2TPTVI2ODVzMUG5
HL-60 MX\GeY5kfGmxbjDBd5NigQ>? M176Z|EvOCEQvF2= MYO0PEBp NEfPW3ll\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= MWCyOVA2OTFzOR?=
HuTu-80  NH\iR4ZHfW6ldHnvckBCe3OjeR?= MlvjNU82NzFyIN88US=> MWi0PE84OiCq NUTEXnBncW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGi3bXHuJG5RSzGOMTDtVm5CKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVyyOFkxPDB4Mh?=
Caco2  MUPGeY5kfGmxbjDBd5NigQ>? NIXUVIUyOCEQvF2= NFX4XFk1QCCq NEn5O|hqdmO{ZXHz[ZMhVlCFMVyxJIV5eHKnc4Ppc44> NIXxfZozPDlyNEC2Ni=>
HepG2  NHzUWZhHfW6ldHnvckBCe3OjeR?= MnPONE0zPSEQvF2= NWTVRndIOjRiaB?= NETWWGll\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6 NXPINVRvOjR6NUW2OFY>
HepG2  Mn3ZSpVv[3Srb36gRZN{[Xl? M{jQe|AuOjVizszN MV6yOEBp NVfVbIxZcW6lcnXhd4V{KGyxdzDk[Y5{cXS7IHzpdI9xem:2ZXnuJJJm[2WydH;yJEhNTEyUKTDn[Y5mKGW6cILld5Nqd28EoB?= MoDYNlQ5PTV4NE[=
HepG2  MmruSpVv[3Srb36gRZN{[Xl? M4rUU|ExKM7:bdMg MnLINE0zPCCq MXPk[YNz\WG|ZYRCpHBEW0t7wrDhcoTDqEiPR1PSxsBmgHC{ZYPzbY9vKGGwZDDpcoNz\WG|ZYOgUGRNWiCneIDy[ZN{cW:wIHHmeIVzKDZiaB?= M4PDOFI1QDV3NkS2
HepG2  NHXGNI1HfW6ldHnvckBCe3OjeR?= MnTPNVAh|ryv M{O1TFI1KGh? MonxdJJwdW:2ZYOgZ5l1d3OxbHnjJI5mfXS{YXygcIlxcWRiYXPjeY12dGG2aX;uJIlv\GWyZX7k[Y51dHlib3[g[Zhw\2Wwb4XzJIxqeG:ycn;0[Ylvew>? MUCyOFg2PTZ2Nh?=
HepG2  NVnBbnhMTnWwY4Tpc44hSXO|YYm= MWSxNEDPxG1? NV;mPFh3OjRiaB?= M1nyN5Bz\X[nboTzJHNTTUKSIIDyc4Nme3Orbne= MUKyOFg2PTZ2Nh?=
HC45  NXzKTG1wTnWwY4Tpc44hSXO|YYm= NVe3dmJHPcL3TdMg Mn;FOEBl MYXy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? MUOyOFc3OjhyOR?=
CNDT2  NEThSHdHfW6ldHnvckBCe3OjeR?= M1i2W|XDvU4EoB?= NG\KT2Q1KGR? MYPy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? M{TiNFI1PzZ{OEC5
CNDT2  NIntZYhHfW6ldHnvckBCe3OjeR?= M3rk[lXDvU4EoB?= Ml\COEBl MYnpcoNz\WG|ZYOg[4Vv\SCneIDy[ZN{cW:wIH;mxsBYUUZzLDDQNVYtKEOGSEGsxsBNSU2DMT|CpIFv\MLiQ2TOUmIy MVSyOFc3OjhyOR?=
T-cells MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HGZVUwOjBizszN MV2wMVQ5KGh? NVXjR|JPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MonRNlQ4PTd{OEO=
CD3+ T-cells NYK2blFzTnWwY4Tpc44hSXO|YYm= MYK1M|IxKM7:TR?= M2fGVFQ5KGh? NHjnXXp2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> MYGyOFc2PzJ6Mx?=
CD4+ T-cells M1zuZ2Z2dmO2aX;uJGF{e2G7 MVy1M|IxKM7:TR?= M4P2d|Q5KGh? MoLzeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= NGTyVGMzPDd3N{K4Ny=>
CD8+ T-cells M1H0SmZ2dmO2aX;uJGF{e2G7 NXLmdZN2PS9{MDFOwG0> MoXDOFghcA>? MmPjeZBz\We3bHH0[ZMheDF3IHX4dJJme3Orb36= NVmxVFdwOjR5NUeyPFM>
CD3+ T-cells NY\HVVlVTnWwY4Tpc44hSXO|YYm= NIOyN5c2NzJyIN88US=> NHPC[3A1QCCq NVzaOVRtfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM> NFv2SGszPDd3N{K4Ny=>
CD4+ T-cells MnTRSpVv[3Srb36gRZN{[Xl? M{SyeVUwOjBizszN M2DJN|Q5KGh? M1ryV5VxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKE[RWGCz M{TXOlI1PzV5Mkiz
CD4+ T-cells MmfYSpVv[3Srb36gRZN{[Xl? Mo[yOU8zOCEQvF2= NWXy[GFDPDhiaB?= MUXy[YR2[2W|IGTCSXQyyqCvUl7BJIV5eHKnc4Ppc44> NXfVW4VoOjR5NUeyPFM>
CD4+ T-cells NE\wOnZHfW6ldHnvckBCe3OjeR?= MYC1M|IxKM7:TR?= NXzQXIxXPDhiaB?= NHzlV3J2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\sLiUl;S{tN1yqB? NHzsXIYzPDd3N{K4Ny=>
CD4+ T-cells MU\GeY5kfGmxbjDBd5NigQ>? MkWyOU8zOCEQvF2= Mn7iOFghcA>? MkT6bY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? M{X3UVI1PzV5Mkiz
CD8+ T-cells NUXCVpdITnWwY4Tpc44hSXO|YYm= MoTEOU8zOCEQvF2= NE\1e3Q1QCCq MlrBbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? MYKyOFc2PzJ6Mx?=
CD3+ T-cells NF7h[2JHfW6ldHnvckBCe3OjeR?= M{nlOlUh|ryP MnvmOFghcA>? NYLzd|BDemWmdXPld{Btd26pLYTldo0hdWWvb4L5JINmdGxicHjlco91gXCn MkPTNlQ4PTd{OEO=
U937 NXLWcHEySXCxcITvd4l{KEG|c3H5 NXHyOohROTBizszN NWLXfYJbPzJiaB?= NVzFU44ycW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M3zJe|I1PjhyOE[1
HL-60 MoLCRZBweHSxc3nzJGF{e2G7 NYHGclh[OTBizszN M1;VN|czKGh? Mn7DbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? Moe2NlQ3QDB6NkW=
MCF7 MW\GeY5kfGmxbjDBd5NigQ>? NVjNPY93PSEQvF2= MlX6OFghcMLi MYXkbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=> MWmyOFY{OzN3MB?=
MCF7 MmK5SpVv[3Srb36gRZN{[Xl? MmjsNVAh|ryP NEXVW5MzPCCqwrC= NVnUfodrcW6mdXPld{B1cGViY3zlZZZi\2Vib3[gZ4F{eGG|ZTC3JIFv\CCSQWLQxsA> M1qzOlI1PjN|M{Ww
MCF7 NEW5cHBHfW6ldHnvckBCe3OjeR?= M3q1dlDjiJNyLkWg{txOyqB? NGXXc3Y4KGR? MYrpcohq[mm2czD0bIUh\3Kxd4ToJG1ETi15IIT1cY9ze3CqZYLld{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW|wrC= NVTZflZuOjR4M{OzOVA>
MCF7 NFr5[FRHfW6ldHnvckBCe3OjeR?= NFv4bmkxNjVizszNxsA> NWnPcmI6OTRiZB?= MmXvdoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI> NG\oXWwzPDZ|M{O1NC=>
MCF7 NHz6cGlHfW6ldHnvckBCe3OjeR?= MVOwMlA26oDVMkCg{txO NH7QPXAyKGR? Ml\wdoVlfWOnczD0bIUh[2yxbnHsJJN2en[rdnHsJI9nKE2FRj23JINmdGy|IHnuJI1wdm:uYYnldkBkfWy2dYLldy=> NIWzdmczPDZ|M{O1NC=>
T47D  M1zmOmZ2dmO2aX;uJGF{e2G7 MofyNE42KM7:TR?= NIHwXVE1KGR? MWjpcohq[mm2czD0eY1wenOyaHXy[UBnd3KvYYTpc44> NWjyVXVmOjR4M{OzOVA>
MCF7 M4\teWZ2dmO2aX;uJGF{e2G7 Moe0NE426oDVMUCg{txO MmHTOFghcMLi M2TIbYlvcGmkaYTzJJRp\SCpYYCgZ4xwe3W{ZTDpckB1cGVid3;1coQhcGWjbHnu[{Bie3OjeR?= NYTTbnMyOjR4M{OzOVA>
MCF7 MnTqSpVv[3Srb36gRZN{[Xl? NXrUepJkOC9zMDFOwG0> NXrINJVQOjRiaB?= NXj5[pZscW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWDl? MV6yOFY{OzN3MB?=
MDA-MB-231  MoCwSpVv[3Srb36gRZN{[Xl? NUK1dHhsOC534pETNVAh|ryP M1\WbVM3KGh? NWP5UYIycW6qaXLpeJMhfGinIH3p[5JifGmxbh?= MlfFNlQ3OzN|NUC=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 ; 

PubMed: 28210112     


AZA and DAC cause DNMT1 depletion in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–5 µM) for 20 hours and DNMT1 protein was detected by Western blotting of cell extracts. Alpha-tubulin was used as a loading control.

c-PARP / p-H2AX / H2AX; 

PubMed: 28210112     


AZA, but not DAC, induces markers of DNA damage and apoptosis in NSCLC cell lines. A549 and H1299 cells were treated with AZA or DAC (0–10 µM) for 48 hours and Western blotting of cell extracts was used to detect DNMT1, cleaved-PARP, phospho-histone-H2AX(䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘

28210112
Immunofluorescence
HMGB1 ; 

PubMed: 29097772     


U2OS cells stably expressing a GFP-HMGB1 fusion were maintained in control conditions (Ctrl), suberoylanilide hydroxamic acid (SAHA), azacitidine (AZA) for 24 h or 48 h, followed by assessment of cytoplasmic GFP-HMGB1 fluorescence intensity (A,B) or endog䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒

29097772
Growth inhibition assay
Cell viability ; 

PubMed: 28210112     


AZA and DAC differentially affect cell viability in a panel of NSCLC cell lines. Viability of A549, H460, and H1299 cells was assessed after 72 hours of treatment with AZA or DAC (0–25 µM). Error bars represent the standard error of mean of 3 independent 䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖

28210112
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
- Collapse
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms 5-AzaC,Ladakamycin
Smiles NC1=NC(=O)N(C=N1)C2OC(CO)C(O)C2O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04172844 Recruiting Drug: Azacitidine|Drug: Venetoclax|Drug: Pevonedistat Acute Myelogenous Leukemia Ehab L Atallah|Medical College of Wisconsin January 13 2020 Phase 1
NCT04214860 Recruiting Drug: APR-246|Drug: Venetoclax|Drug: Azacitidine Myeloid Malignancy Aprea Therapeutics December 13 2019 Phase 1
NCT04128020 Recruiting Drug: Nivolumab|Drug: Azacitidine Aml|AML Adult Sherif Farag|Big Ten Cancer Research Consortium October 10 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) supplier | purchase Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) cost | Azacitidine (5-Azacytidine) manufacturer | order Azacitidine (5-Azacytidine) | Azacitidine (5-Azacytidine) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID